Chemotherapy Induced Anemia Epidemiology Forecast, Diagnosis, Treatment Options | DelveInsight

April 04 03:44 2020
Chemotherapy Induced Anemia Epidemiology Forecast, Diagnosis, Treatment Options | DelveInsight

‘Chemotherapy Induced Anemia – Epidemiology Forecast to 2030’

 

DelveInsight launched a new report on ‘Chemotherapy Induced Anemia – Epidemiology Forecast to 2030’

DelveInsight’s ‘Chemotherapy Induced Anemia – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Chemotherapy Induced Anemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Some of the facts of the report

1. The incidence of anemia was greater in patients with advanced stages.
2. The risk of grade 2+ anemia was increased from 29% in stage I to 49% in stage IV.
3. The incidence of anaemia in cancer patients reported in literature varies significantly, ranging from 20% to 60% at the time of cancer diagnosis and reaching 60–90% during cancer treatments.

“According to the available literature, no gender bias as been observed in case of Chemotherapy-

Induced Anemia.”

Anemia is the most common and persistent hematological abnormality in oncology patients. Chemotherapy-induced anemia (CIA) is a consequence of malignant invasion of normal tissue leading to blood loss, bone marrow infiltration with disruption of erythropoiesis, and functional iron deficiency as a consequence of inflammation. • Fatigue is the most common symptom of CIA, although vertigo, loss of appetite, poor concentration, and dyspnea are also frequently reported. Grade of anemia in combination with type of cancer and baseline cardiopulmonary function contribute to symptom severity.

The risk and severity of anemia during chemotherapy vary significantly depending on the type, schedule, and intensity of treatments, and whether the patient has received previous myelosuppressive chemotherapy or radiation therapy, as well as the patient’s underlying medical conditions.  Current practices to treat CIA include packed red blood cell transfusions, erythropoietin stimulating agents (ESAs), and iron supplementation. In addition to novel screening mechanisms, various hormones and pharmacologic agents influence the prevention and management of CIA.

Novel treatment options, along with increasing awareness regarding CIA, are responsible for the growth of the therapeutic market.

Request for sample pages : https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-epidemiology-forecast

 

“According to DelveInsight, The increase in market size is a direct consequence of increasing incident population of cancer patients in the 7MM.”

Scope of the Report

  • The Chemotherapy Induced Anemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Chemotherapy Induced Anemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Chemotherapy Induced Anemia in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Chemotherapy Induced Anemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Chemotherapy Induced Anemia
  • The report provides the segmentation of the Chemotherapy Induced Anemia epidemiology

 

KOL- Views

We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

 

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chemotherapy Induced Anemia?
  • What are the key findings pertaining to the Chemotherapy Induced Anemia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Chemotherapy Induced Anemia across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Chemotherapy Induced Anemia?
  • What are the currently available treatments of Chemotherapy Induced Anemia?

 

Request for sample pages : https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-epidemiology-forecast

 

Reasons to buy

  • The Chemotherapy Induced Anemia Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Chemotherapy Induced Anemia market
  • Quantify patient populations in the global Chemotherapy Induced Anemia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chemotherapy Induced Anemia therapeutics in each of the markets covered
  • Understand the magnitude of Chemotherapy Induced Anemia population by its epidemiology
  • The Chemotherapy Induced Anemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Related Reports:

Chemotherapy Induced Anemia – Pipeline Insights, 2020

The Chemotherapy Induced Anemia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Chemotherapy Induced Anemia across the complete product development cycle, including all clinical and nonclinical stages.

Chemotherapy Induced Anemia- Market Insight, Epidemiology and Market Forecast -2030

The Chemotherapy Induced Anemia market report provides current treatment practices, emerging drugs, Chemotherapy Induced Anemia market share of the individual therapies, current and forecasted Chemotherapy Induced Anemia market Size from 2017 to 2030 segmented by seven major markets. 

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/